Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Return on Equity (2021 - 2025)

Xeris Biopharma Holdings' Return on Equity history spans 5 years, with the latest figure at 0.09% for Q4 2025.

  • For the quarter ending Q4 2025, Return on Equity fell 181.0% year-over-year to 0.09%, compared with a TTM value of 0.09% through Dec 2025, down 181.0%, and an annual FY2025 reading of 0.07%, down 308.0% over the prior year.
  • Return on Equity for Q4 2025 was 0.09% at Xeris Biopharma Holdings, down from 1.55% in the prior quarter.
  • The five-year high for Return on Equity was 42.68% in Q4 2023, with the low at 10.76% in Q3 2021.
  • Average Return on Equity over 5 years is 1.49%, with a median of 1.44% recorded in 2022.
  • Year-over-year, Return on Equity soared 4457bps in 2023 and then crashed -4079bps in 2024.
  • Tracing XERS's Return on Equity over 5 years: stood at 2.65% in 2021, then rose by 29bps to 1.89% in 2022, then soared by 2360bps to 42.68% in 2023, then plummeted by -96bps to 1.89% in 2024, then crashed by -95bps to 0.09% in 2025.
  • Per Business Quant, the three most recent readings for XERS's Return on Equity are 0.09% (Q4 2025), 1.55% (Q3 2025), and 1.18% (Q2 2025).